287 related articles for article (PubMed ID: 25389924)
1. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.
Wei IH; Harmon CM; Arcerito M; Cheng DF; Minter RM; Simeone DM
Ann Surg; 2014 Dec; 260(6):1088-94. PubMed ID: 25389924
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
3. Cystic pancreatic neuroendocrine tumors: outcomes of preoperative endosonography-guided fine needle aspiration, and recurrence during long-term follow-up.
Ridtitid W; Halawi H; DeWitt JM; Sherman S; LeBlanc J; McHenry L; Coté GA; Al-Haddad MA
Endoscopy; 2015 Jul; 47(7):617-25. PubMed ID: 25763832
[TBL] [Abstract][Full Text] [Related]
4. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
[TBL] [Abstract][Full Text] [Related]
5. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.
Genç CG; Jilesen AP; Partelli S; Falconi M; Muffatti F; van Kemenade FJ; van Eeden S; Verheij J; van Dieren S; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg; 2018 Jun; 267(6):1148-1154. PubMed ID: 28594340
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of nonresected main-duct intraductal papillary mucinous neoplasms of the pancreas.
Daudé M; Muscari F; Buscail C; Carrère N; Otal P; Selves J; Buscail L; Bournet B
World J Gastroenterol; 2015 Mar; 21(9):2658-67. PubMed ID: 25759534
[TBL] [Abstract][Full Text] [Related]
7. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.
Kishi Y; Shimada K; Nara S; Esaki M; Hiraoka N; Kosuge T
Ann Surg Oncol; 2014 Sep; 21(9):2882-8. PubMed ID: 24740828
[TBL] [Abstract][Full Text] [Related]
8. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.
Bilimoria KY; Talamonti MS; Tomlinson JS; Stewart AK; Winchester DP; Ko CY; Bentrem DJ
Ann Surg; 2008 Mar; 247(3):490-500. PubMed ID: 18376195
[TBL] [Abstract][Full Text] [Related]
9. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors.
Chouliaras K; Newman NA; Shukla M; Swett KR; Levine EA; Sham J; Mann GN; Shen P
J Surg Oncol; 2018 Sep; 118(3):416-421. PubMed ID: 30259518
[TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory Forkhead Box Protein p3-Positive Lymphocytes Are Associated with Overall Survival in Patients with Pancreatic Neuroendocrine Tumors.
de Reuver PR; Mehta S; Gill P; Andrici J; D'Urso L; Clarkson A; Mittal A; Hugh TJ; Samra JS; Gill AJ
J Am Coll Surg; 2016 Mar; 222(3):281-7. PubMed ID: 26809747
[TBL] [Abstract][Full Text] [Related]
11. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor.
Yamamoto Y; Okamura Y; Uemura S; Sugiura T; Ito T; Ashida R; Kato Y; Ohgi K; Yamada M; Sasaki K; Aramaki T; Uesaka K
Ann Surg Oncol; 2017 Aug; 24(8):2363-2370. PubMed ID: 28271173
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
Sallinen V; Haglund C; Seppänen H
Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
[TBL] [Abstract][Full Text] [Related]
13. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.
Harimoto N; Hoshino K; Muranushi R; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Araki K; Hosouchi Y; Suzuki H; Arakawa K; Hirai K; Fukazawa T; Ikota H; Shirabe K
Pancreatology; 2019 Sep; 19(6):897-902. PubMed ID: 31409525
[TBL] [Abstract][Full Text] [Related]
15. Reappraisal of central pancreatectomy a 12-year single-center experience.
Goudard Y; Gaujoux S; Dokmak S; Cros J; Couvelard A; Palazzo M; Ronot M; Vullierme MP; Ruszniewski P; Belghiti J; Sauvanet A
JAMA Surg; 2014 Apr; 149(4):356-63. PubMed ID: 24740703
[TBL] [Abstract][Full Text] [Related]
16. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
17. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
18. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
[TBL] [Abstract][Full Text] [Related]
19. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor.
Nanno Y; Matsumoto I; Zen Y; Otani K; Uemura J; Toyama H; Asari S; Goto T; Ajiki T; Okano K; Suzuki Y; Takeyama Y; Fukumoto T; Ku Y
Ann Surg Oncol; 2017 Apr; 24(4):1127-1133. PubMed ID: 27822631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
